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Abstract 
Background: Cerebrospinal fluid (CSF) is a proximal fluid which communicates closely with brain tissue, contains 
numerous brain-derived proteins and thus represents a promising fluid for discovery of biomarkers of central nervous 
system (CNS) diseases. The main purpose of this study was to generate an extensive CSF proteome and define brain-
related proteins identified in CSF, suitable for development of diagnostic assays.
Methods: Six non-pathological CSF samples from three female and three male individuals were selected for CSF 
analysis. Samples were first subjected to strong cation exchange chromatography, followed by LC-MS/MS analysis. 
Secreted and membrane-bound proteins enriched in the brain tissues were retrieved from the Human Protein Atlas.
Results: In total, 2615 proteins were identified in the CSF. The number of proteins identified per individual sample 
ranged from 1109 to 1421, with inter-individual variability between six samples of 21 %. Based on the Human Protein 
Atlas, 78 brain-specific proteins found in CSF samples were proposed as a signature of brain-enriched proteins in CSF.
Conclusion: A combination of Human Protein Atlas database and experimental search of proteins in specific body 
fluid can be applied as an initial step in search for disease biomarkers specific for a particular tissue. This signature may 
be of significant interest for development of novel diagnostics of CNS diseases and identification of drug targets.
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Background
Cerebrospinal fluid (CSF) is a proximal fluid residing in 
direct contact with the cerebral parenchyma. CSF acts to 
protect, support and nurture brain tissues and is essen-
tial for brain functioning. Apart from hydro-mechanical 
protection, CSF is also important for the homeostasis of 
the extracellular environment and hormonal-to-neuro-
peptide balance in the central nervous system (CNS) [1, 
2]. The majority of CSF is produced as plasma ultra-fil-
trate by the choroid plexus in the lateral, third and fourth 
ventricles, whereas a smaller portion is derived from the 
cerebral interstitial fluid and cerebral capillaries [3]. CSF 
production is a dynamic process with a rate of about 
500 mL per day, and CSF absorption is mainly performed 
through arachnoid villi from the subarachnoid space into 
the venous sinuses [3]. Approximately 80  % of the total 
CSF protein is derived from the plasma, upon crossing 
the blood–brain barrier, and another 20 % is secreted by 
the CNS [1]. Examples of proteins with higher CSF con-
centration and high CSF-to-blood serum ratios include 
prostaglandin D2 synthase (ratio 34/1), S-100B (18/1), 
tau protein (10/1), and cystatin C (5/1) [4, 5]. The most 
abundant blood-derived proteins in CSF are albumin and 
immunoglobulins. Blood-related proteins in CSF such 
as apolipoprotein B-100 and hemoglobin are commonly 
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Detailed composition of the CSF proteome may pro-
vide novel insights for the in-depth understanding of 
CNS functioning under physiological and pathological 
conditions. The advantages of tissue-specific proteomes 
have been previously demonstrated for the discovery 
of novel protein biomarkers [7, 8]. The Human Pro-
tein Atlas (HPA) provides comprehensive data on the 
tissue-specific transcriptome and proteomes, based on 
the RNA-sequencing analysis of 32 human tissues and 
immunohistochemistry analysis of 44 tissues, respec-
tively [9]. Apart from the tissue-specific proteomes, 
HPA includes comprehensive summaries of regulatory, 
secreted and membrane, cancer-specific and druggable 
proteomes. This makes HPA an indispensable repository 
of the human proteome and its applications for disease 
diagnostics and drug discovery. It is worth noting that 
brain is the top second organ with the largest number of 
tissue-specific genes. From the 1134 elevated genes in the 
brain, 315 are tissue-enriched genes, 226 genes are found 
to be elevated in a group of 2–7 tissues and 590 genes 
are annotated as tissue-enhanced genes. Tissue-enriched 
genes are considered genes with mRNA expression at 
least five times higher in the cerebral cortex relative to 
other tissues, while group-enriched genes have mRNA 
expression at least five times higher in the group of 2–7 
tissues, including cerebral cortex, relative to all other 
tissues. Lastly, tissue-enhanced genes have at least five 
times higher mRNA expression in brain relative to the 
average expression in all other tissues. The gene ontol-
ogy (GO) analysis of the elevated genes indicates that 
the main functions of brain proteins are synaptic trans-
mission and neurological processes, whereas most of the 
brain-enriched genes are membrane-bound or secreted 
proteins. Interestingly, membrane-bound and secreted 
proteins represent the majority of the CSF proteome and 
their fraction is much higher in CSF than in blood [1, 
10]. Considering that membrane and secreted proteins 
are overrepresented in the CSF, they could be potentially 
reliably identified and quantified, which makes them 
respectable biomarker candidates. Besides, significant 
amounts of membrane-shed and secreted proteins may 
be released into proximal fluids (such as CSF); these pro-
teins have been previously suggested as promising bio-
marker candidates of various diseases [11, 12].
The field of CSF proteomics is constantly expanding and 
many efforts have been made to characterize the CSF pro-
teome. The most extensive CSF protein mapping to date, by 
Zhang et al., identified 3256 proteins [10], and by Guldbrand-
sen et al., identified 3081 proteins [13], followed by Schutzer 
et al. with 2630 [14], and Pan et al. with 2594 proteins [15].
The main purpose of the present study was to expand 
the knowledge of the human CSF proteome and gener-
ate a panel of brain-enriched proteins that can potentially 
serve as a platform for biomarker discovery of CNS dis-
eases. Here, we performed two-dimensional chroma-
tography (off-line strong-cation exchange fractionation 
followed by the on-line reverse-phase separation) and 
mass spectrometry analysis to generate the extensive 
proteome of normal CSF samples. HPA data was further 
applied to select brain-related secreted and membrane-
bound proteins found in the CSF. Since high-quality 
antibodies and ELISAs may not be available for many 
brain tissue-specific proteins, we provided a list of brain-
enriched proteins detectable by mass spectrometry and 
thus quantifiable in CSF by antibody-free selected reac-
tion monitoring (SRM) assays [16, 17].
Methods
Cerebrospinal fluid sample preparation
Six non-pathological (normal) CSF samples were retro-
spectively retrieved for CSF proteome analysis as samples 
archived after routine biochemical examinations at the 
Mount Sinai Hospital, Toronto and stored at −80 °C until 
further use. All samples were transparent, clear and with-
out any visible blood contamination. The patients’ age 
ranged from 32 to 72 years and included three female and 
three male patients. The ethical approval was obtained 
from the Mount Sinai Hospital Research Ethics Board.
For the CSF proteomic analysis, samples were thawed 
at room temperature, centrifuged for 10  min at 17,000g 
and subjected to mass spectrometry sample preparation. 
Each CSF sample was adjusted to a volume equivalent 
to 300 µg total protein, denatured with 0.05 % RapiGest 
(Waters, Milford, USA) and reduced with 5  mM dithi-
othreitol (Sigma-Aldrich, Oakville, Canada) at 60  °C for 
40 min. Alkylation was achieved with 15 mM iodoaceta-
mide (Sigma-Aldrich, Oakville, Canada) for 60  min in 
the dark at room temperature. Protein digestion was car-
ried out with trypsin (Sigma-Aldrich, Oakville, Canada) 
in 50 mM ammonium bicarbonate (1:30 trypsin to total 
protein ratio), for 18 h at 37 °C. Digestion and RapiGest 
cleavage were completed with 1  % trifluoroacetic acid 
following sample centrifugation at 500g for 30 min. Sam-
ples were frozen at −80 °C until strong-cation exchange 
(SCX) HPLC peptide separation.
Strong cation exchange chromatography
Trypsinized samples were diluted two-fold with the 
SCX Buffer A (0.26 M formic acid, 5 % acetonotrile) and 
loaded on the SCX PolySULFOETHYL Column (The 
Nest Group, Inc, Southborough, USA) coupled to the 
Agilent 1100 HPLC system. The peptides were eluted 
with the gradual increase of the SCX Buffer B (0.26  M 
formic acid, 5  % acetonitrile, 1  M ammonium formate) 
during the 70 min gradient (30–40 min 20 % SCX Buffer 
B; 45–55  min 100  % SCX Buffer B) and a flow rate of 
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200  µL/min. The eluent was monitored at 280  nm and 
fractions (400  µL) were collected. Based on the elution 
profile, 15 individual fractions and one pooled fraction 
(for low absorbance fractions, at the end of the gradient) 
per sample were selected for mass spectrometry analysis. 
Peptides were purified by extraction using OMIX C18 
tips, eluted with 5 µL of acetonitrile solution (65 % ace-
tonitrile, 0.1 % formic acid) and finally diluted with 60 µL 
of water-formic acid (0.01 % formic acid) solution.
Liquid chromatography–tandem mass spectrometry 
(LC‑MS/MS)
In total, 96 desalted SCX fractions from six individual 
CSF samples were loaded on the 96 well-plate. Using an 
auto-sampler, 18 µL of each sample were injected into an 
in-house packed 3.3 cm trap pre-column (5 μm C18 par-
ticle, column inner diameter 150 μm) and peptides were 
eluted from the 15 cm analytical column (3 μm C18 par-
ticle, inner diameter 75 μm, tip diameter 8 μm). The liq-
uid chromatography, EASY-nLC system (Thermo Fisher, 
Odense, Denmark) was coupled online to the Q-Exactive 
Plus (Thermo Fischer, San Jose, USA) mass spectrometer 
with a nanoelectrospray ionization source. The 60-min 
liquid-chromatography (LC) gradient was applied with 
an increasing percentage of buffer B (0.1  % formic acid 
in acetonitrile) for peptide elution; at the flow rate of 
300  nL/min. Full MS1 scan was acquired from 400 to 
1500  m/z in the Orbitrap at a resolution of 70,000, fol-
lowed by the MS2 scans on the top 12 precursor ions at 
a resolution of 17,500 in a data-dependent acquisition 
(DDA) mode. The dynamic exclusion was enabled for 
45  s and unassigned charge, as well as charge states +1 
and +4 to ≥8 were omitted from MS2 fragmentation.
Data analysis
The Human Protein Atlas (HPA) [9] version 13 (the tis-
sue specific proteome database) was utilized to generate 
a list of secreted and membrane-bound brain-expressed 
proteins that had high mRNA expression in the brain rela-
tive to other human tissues. The list of 318 brain-enriched 
proteins (with mRNA expression at least 5 times higher 
in the cerebral cortex relative to other tissues) and 226 
group-enriched proteins (with mRNA expression at least 
5 times higher in the group of 2–7 tissues, including cer-
ebral cortex) was downloaded from the HPA database 
(www.proteinatlas.org). Brain-related proteins were then 
merged with the secretome (n =  3171 proteins) and the 
membrane proteome (n = 5570 proteins), generated based 
on the prediction algorithms for membrane and secreted 
proteins. Immunohistochemistry-based expression (IHC) 
of the candidate proteins were manually assessed using 
the HPA database. Validation data were annotated as IHC 
brain evidence (detected, not detected, NA—not available) 
and IHC tissue expression (number of tissues protein is 
expressed/total number of tissues evaluated), considering 
four brain-derived tissues as a single tissue.
Raw files were uploaded into the Proteome Discov-
erer, version 1.4 (Thermo Fischer, San Jose, USA), and 
searched with both Mascot and Sequest HT algorithms 
against the human TrEMBL database (July 2014 release). 
Searching parameters included: two maximum missed 
cleavages, cysteine carbamidomethylation as a static 
modification, methionine oxidation as a dynamic modi-
fication, precursor mass tolerance of 7  ppm, fragment 
mass tolerance of 0.02 Da. Proteins were grouped auto-
matically by Proteome Discoverer software and the mas-
ter protein per group was assigned by the Parsimony 
Principle. Decoy database search was set to 1  % false 
discovery rate at the peptide level. The final list of brain-
enriched and group-enriched candidates was selected 
based on protein identification in at least 4 out of 6 indi-
vidual samples. Brain-enriched (n  =  196) and group-
enriched (n  =  138) proteins were first retrieved from 
HPA, merged with secreted/membrane proteome to gen-
erate a list of brain/group enriched secreted/membrane 
proteins which were then merged with the in-house gen-
erated CSF proteome (based on the gene name) using 
R statistical software version 2.15.2 (www.Rproject.
org). Label-free quantification of the CSF proteome and 
78 candidate proteins was performed using MS1 area 
obtained with Proteome Discoverer (v1.4). Venn diagram 
for inter-individual sample reproducibility was prepared 
using Jvenn [18]. The GO analysis of candidate proteins 
was executed with PANTHER classification system [19]. 
The comparison between in-house developed CSF pro-
teome and CSF proteome from the literature (Guld-
brandsen et al. and Zhang et al.) was performed with R 




To generate an in-house CSF proteome of wide age range 
of healthy individuals, six non-pathological CSF sam-
ples from three female and three male individuals were 
selected (Fig. 1), with patients’ age from 32 to 72 years. 
Numbers of identified proteins in each individual CSF 
sample ranged from 1109 to 1421, while numbers of iden-
tified peptides varied from 6272 to 8632 at 1  % FDR at 
the peptide level. Merging of proteomes of six individuals 
resulted in 2615 proteins (12,443 peptides) which repre-
sented our complete CSF proteome. Table 1 includes the 
number of proteins and peptides identified in all 6 CSF 
samples.
Between any two samples, the average percentage 
of common proteins was 66.9  %. Fewer proteins were 
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common between 3 and 6 samples. Specifically, 1183 
(45.4  %) proteins were common in at least 3 samples, 
947 (36.2 %) in at least 4 samples, 734 (28.1 %) proteins 
were shared with at least 5 samples, while 546 (20.9  %) 
were shared among all 6 samples (Fig. 2; Table 2; Addi-
tional file  1: figure  1). At the peptide level, the average 
percentage of peptides common between any two sam-
ples was 74 %. Similar to proteins, fewer number of pep-
tides where common among more samples. 7423 (59.7 %) 
identified peptides were shared among at least 3 samples, 
6138 (49.3 %) between at least 4 samples, 4937 (39.7 %) 
peptides between at least 5 samples, while 3625 (29.1 %) 
were shared among all 6 samples (Fig. 3; Table 3; Addi-
tional file 2: figure 2).
Identification of brain‑related proteins in the CSF 
proteome
According to our analysis, the total number of tissue-
enriched and group-enriched proteins with HPA evi-
dence of high mRNA expression in the brain was 318 
and 226, respectively. Of those, 196 tissue-enriched and 
138 group-enriched proteins were secreted and/or mem-
brane proteins (Additional file  3: Table  1, Additional 
file 4: Table 2).We then examined our CSF proteome for 
the presence of those 196 tissue-enriched and 138 group-
enriched proteins (Fig. 1).
Less than 30  % of brain-enriched (33 proteins) or 
group-specific proteins (24) were found in all six CSF 
replicates. Additional proteins can be found in at least 
4 or 5 out of the 6 replicate samples. In total, 78 brain-
related proteins (secreted or membrane-bound) were 
found in CSF of at least 4 different individuals. Additional 




























Fig. 1 Candidate selection workflow. Six individual CSF samples were digested, fractionated with SCX–HPLC and analyzed with LC-MS, MS/MS to 
generate in-house human CSF proteome. 196 brain-enriched and 138 group-enriched proteins (secreted/membrane) were compared against indi-
vidual CSF proteome and 78 brain-related proteins, found reproducibly in individual CSF samples, were selected. A absorbance, RI relative intensity, 
m/z mass-to-charge ratio
Table 1 Number of identified proteins and peptides in six 
individual CSF samples
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file  5: Table  3 contains the list of all proteins with their 
relative abundance in CSF based on average area (AA), 
average number of unique peptides, RNA tissue-specific 
score (RNA TS) and IHC evidence based on HPA. Based 
on these experimental data, tissue-enriched proteins with 
the highest abundance in CSF were amyloid-like protein 
1, APLP1 (AA = 1.07 × 1010) with average number of 9 
unique peptides identified, followed by secretogranin-3, 
SCG3 (AA  =  7.98  ×  109 and 24 unique peptides). Of 
the HPA proteins identified in CSF, V-set and trans-
membrane domain-containing protein 2B, VSTM2B 
(RNA TS  =  108) and neurocan core protein, NCAN 
(RNA TS = 60) had the highest RNA TS. In the group-
enriched proteins, the most abundant proteins were 
kallikrein-6, KLK6 (AA  =  1.61  ×  1010; 14 unique pep-
tides) and secreted phosphoprotein 1/osteopontin, SPP1 
Fig. 2 Venn diagram of proteins identified in 6 individual CSF samples. Total number of identified proteins in all samples was 2615 with 546 (21 %) 
common proteins for all 6 samples. Number of individual proteins ranged from 1109 to 1421
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(AA  =  1.32  ×  1010; 10 unique peptides). Neurexophi-
lin-1, NXPH1 (RNA TS =  44) and contactin-associated 
protein-like 5, CNTNAP5 (RNA TS = 16) had the high-
est RNA TS. Figure 4 shows tissue-enriched and group-
enriched candidates and their abundance in CSF. In 
addition, the validation of the KLK6 at the protein level 
in brain tissues and CSF pool was performed using SRM 
assay. These findings, together with the methods used, 
were reported in the Additional file  6: Supplementary 
method and Additional file  7: figure  3. To compare the 
relative abundance (based on MS1 area) of selected 78 
proteins over the relative abundance of the complete CSF 
proteome, we plotted MS1 areas of candidate proteins 
over the MS1 area of all identified proteins (Fig. 5). As a 
result, most of 78 proteins were positioned in the mid-
dle and the upper range of the complete CSF proteome 
relative abundance. The indication of such candidate dis-
tribution suggests that the abundance of the 78 proteins 
is medium to high when compared to the CSF proteome 
and thus will be measurable by SRM assays in CSF sam-
ples. Knowledge of protein abundances is important to 
predict if proteins could be quantified in clinical samples 
using SRM assays, as we previously demonstrated for 
testis-specific proteins in seminal plasma [16]. The most 
represented GO molecular functions of 78 proteins were 
binding (35 % of proteins) and receptor activity (33 % of 
proteins) as shown in Fig. 6.
Cell type‑specific brain‑related proteins in the CSF 
proteome
Given that HPA also contains data on IHC staining of 
proteins in several brain regions (hippocampus, lateral 
ventricle, cortex and cerebellum) and cell types, we ana-
lyzed the CSF proteins in order to identify brain region- 
and cell-type specific proteins. Since some CNS diseases 
originate in specific regions [20, 21] or cell types [21], 
measurement of CSF proteins with specific expression in 
the corresponding regions or cell types may pinpoint the 
pathological process with high diagnostic sensitivity. Pro-
teins with staining specific for a single cell type are shown 
in Table  4. The neuron-specific proteins included neu-
rosecretory protein VGF, receptor-type tyrosine-protein 
phosphatase-like N and neurexophilin-1, neuropil spe-
cific, neurocan core protein, tenascin-R and cell adhesion 
molecule 3, while protein with specific staining for the 
Purkinje cells was transmembrane protein 132D. Immu-
nohistochemical images of these proteins can be found at 
the HPA website (http://www.proteinatlas.org).
Discussion
The prime goal of this study was to generate compre-
hensive proteome of normal CSF samples and define 
brain-related proteins identified in the generated pro-
teome. In order to obtain in-depth proteome coverage 
of normal CSF and allow for identification of low abun-
dance proteins, we performed off-line SCX fractiona-
tion of individual CSF samples, followed by LC-MS/MS 
analysis. The Q Exactive Plus mass spectrometer pro-
vided high-resolution, high mass accuracy, wide dynamic 
range and excellent sensitivity, and along with the ben-
efit of pre-fractionation strategy, facilitated identification 
of the extensive CSF proteome. With a total number of 
2615 identified proteins, this study provides additional 
information about the CSF proteome when compared to 
previous proteomic studies [13–15, 22–24]. Recent stud-
ies of CSF identified similar number of proteins, utilizing 
different separation methodologies and mass spectrome-
try-based proteomics [10, 13–15].
We compared our CSF proteome to the CSF proteome 
identified by Guldbrandsen et al., with 3081 protein sets 
or 2875 protein groups reported (available from: http://
probe.uib.no/csf-pr) and by Zhang et al. with 2513 pro-
teins reported with at least two unique peptides. When 
CSF proteins from both studies were compared against 
our proteome, the combined CSF proteome consisted of 
4649 proteins and 4346 proteins for Guldbrandsen et al. 
plus our proteome and Zhang et  al. plus our proteome, 
respectively. Overall, the combined CSF proteome for 
all three studies consisted of 5133 proteins. The number 
of overlapping proteins between Guldbrandsen and our 
study was 819 (18 % of the combined proteomes, 31 % of 
Table 2 Overlap of proteins in individual samples
a Among 2615 proteins




CSF1 and CSF2 859 71.6 67.0
CSF1 and CSF3 757 63.1 68.3
CSF1 and CSF4 823 68.6 57.9
CSF1 and CSF5 827 68.9 63.4
CSF1 and CSF6 787 65.6 63.4
CSF2 and CSF3 794 61.9 71.6
CSF2 and CSF4 924 72.1 65.0
CSF2 and CSF5 900 70.2 69.0
CSF2 and CSF6 841 65.6 67.8
CSF3 and CSF4 780 70.3 54.9
CSF3 and CSF4 771 69.5 59.1
CSF3 and CSF6 752 67.8 60.6
CSF4 and CSF5 894 62.9 68.5
CSF4 and CSF6 859 60.5 69.2
CSF5 and CSF6 843 64.6 67.9
Common in all 6 CSFsa 546 20.9 NA
Common in at least 5 CSFs 734 28.1 NA
Common in at least 4 CSFs 947 36.2 NA
Common in at least 3 CSFs 1188 45.4 NA
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our proteome), with 2034 proteins detected only in the 
Guldbrandsen study, and 1796 only in the present study. 
Similarly, the number of overlapping proteins between 
Zhang et al. and our study was 782 (18 % of the combined 
proteomes, 30  % of our proteome), with 1731 proteins 
detected only in Zhang study, and 1833 only in the pre-
sent study. In addition, number of unique proteins, iden-
tified only in this study, was 1764. These discrepancies 
in CSF proteins are partially due to the different prot-
eomic workflows and other technical differences. For 
example, Guldbrandsen et  al. used three different sepa-
ration approaches (immuno-depletion, SDS-PAGE, MM 
PR-AX, glycoprotein enrichment) while we used a sin-
gle (SCX) strategy. However, inter-individual variation 
of CSF composition seems to be the major factor since 
only 21 % of our identified proteins were common in all 
Fig. 3 Venn diagram of peptides identified in 6 individual CSF samples. Total number of identified proteins in all samples was 12,443 with 3625 
(29 %) common proteins for all 6 samples. Number of individual proteins ranged from 6272 to 8632
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6 samples. The fact that there are numerous unique pro-
teins identified among the different groups indicates a 
need for more studies, in order to have a complete pic-
ture of the CSF proteome. In addition, pre-analytical 
variables should be standardized allowing for reliable and 
comparable proteomic research.
It should also be noted that availability of high-quality 
clinical samples represents a recognized issue in the field 
of biomarker discovery [25]. Most of the previous studies 
employed pools of CSF samples for protein identification. 
Here, we analyzed individual samples in order to obtain 
complete CSF proteome and to evaluate inter-individual 
reproducibility. The biological reproducibility among six 
individual samples indicated that only 21  % of the pro-
teins were common to all samples, which led us to the 
conclusion that the inter-individual heterogeneity was 
an important contributor to variation of CSF proteins, 
as also observed in previous studies [14, 26]. Some of the 
inter-individual differences could be explained by sex and 
age differences [22, 27]. Sample size for this comparison 
is relatively small and sex differences should be further 
examined. Although the samples in this study cover a 
wide age range, the age influence on CSF proteome com-
position was not within the scope of this study.
CSF analysis can be affected by several pre-analytical 
parameters, such as variability of sample collection 
tubes, stability, sample storage and other parameters 
which should be standardized [28, 29]. One of the com-
mon pre-analytical parameters that can affect the CSF 
protein composition is blood contamination, possibly 
introduced during the lumbar puncture procedure. Pro-
tein concentration in CSF is much lower compared to 
blood (approximately 150 times lower). Therefore, even 
a small blood contamination can significantly increase 
the protein amount in the CSF and have an impact on 
qualitative and quantitative analysis of CSF proteome. 
In order to ensure the quality of the CSF samples in 
this study, visual and biochemical analysis was made 
and samples with no visible blood contamination or 
xanthochromia were selected. We also sought to deter-
mine the contribution of plasma proteins in our CSF 
proteome. The database of 1050 plasma proteins gener-
ated by Guldbrandsen et al. (http://probe.uib.no/csf-pr) 
was utilized. The number of proteins common to CSF 
and blood plasma was 415, indicating that 2200 proteins 
were unique to the CSF.
CSF communicates closely with brain tissue, and as 
such it can be considered an ideal specimen for bio-
marker discovery of CNS diseases and basic neurosci-
ence research. Thus, the following goal of the study was 
to create a signature of highly specific brain-derived 
proteins identified in our CSF proteome. HPA-based 
brain-specific proteome (defined here as combining tis-
sue-enriched and group-enriched proteins from HPA) 
was utilized for candidate selection. Only proteins of 
secreted or membrane origin were considered. A list of 
78 brain-specific proteins found in at least 4 out of 6 of 
our CSF proteomes, was generated (Fig.  4; Additional 
file 5: Table 3). Overall, 57 (52 %) of the brain-related pro-
teins (identified in the CSF proteome) were present in 
all six individual proteomes, 67 (61 %) in at least 5 pro-
teomes, 78 (72 %) in at least 4 proteomes, 85 (78 %) in at 
least 3 proteomes and 95 (87 %) in at least 2 proteomes 
(data not shown). In addition, 95 and 96  % of the can-
didates were found in the proteome of Zhang et al. and 
Guldbrandsen et  al., respectively. We intend to develop 
highly accurate and specific SRM assays for their quan-
tification in different neurological diseases, to determine 
their potential as diagnostic or prognostic biomarkers. 
For some of the candidates, no commercial antibodies 
have been developed, resulting in limited information 
about their distribution and concentration in the brain 
tissues or CSF (for example, VSTM2B protein previously 
linked to pathogenesis of ataxia telangiectasia [30]). Fur-
thermore, highly specific brain proteins identified in this 
study could reveal new pathways or disease mechanisms 
and lead to discovery of novel therapeutic targets. How-
ever, some possible limitations of the biomarker discov-
ery approach utilized in this study should be considered. 
In a disease state, due to the neuronal cell’s degeneration, 
Table 3 Overlap of peptides in individual samples
a Among 2615 proteins






CSF1 and CSF2 5696 81.6 74.7
CSF1 and CSF3 4982 71.4 79.4
CSF1 and CSF4 5502 78.8 63.7
CSF1 and CSF5 5367 76.9 74.0
CSF1 and CSF6 5003 71.7 74.1
CSF2 and CSF3 5180 67.9 82.6
CSF2 and CSF4 6181 81.0 71.6
CSF2 and CSF5 5748 75.3 79.2
CSF2 and CSF6 5276 69.2 78.1
CSF3 and CSF4 5102 81.3 59.1
CSF3 and CSF5 4988 79.5 68.8
CSF3 and CSF6 4633 73.9 68.6
CSF4 and CSF5 5815 67.4 80.2
CSF4 and CSF6 5415 62.7 80.2
CSF5 and CSF6 5199 71.7 77.0
Common in all 6 CSFsa 3625 29.1 NA
Common in at least 5 CSFs 4937 39.7 NA
Common in at least 4 CSFs 6138 49.3 NA
Common in at least 3 CSFs 7423 59.7 NA
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some of the intracellular proteins could be released in the 
extracellular space or secreted into the CSF. Any immune 
cells recruited to the lesion may also secrete proteins 
into the CSF, although these would not be considered 
brain-specific. These proteins would thus remain unde-
tected by our study.
Notably, some of the proteins found in CSF have been 
previously linked to neurodegenerative diseases. For 
Fig. 4 CSF brain tissue-enriched and group-enriched proteins and their relative abundance. a 45 brain-enriched and b 33 group-enriched proteins 
were detected in at least 4 out of 6 CSFs samples, and the average MS1 area was used as a proxy of protein abundance. Abundance is indicated for 
representative protein isoform. Shaded bars show proteins that are detected in all 6 samples
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example, APLP1, is a membrane-bound glycoprotein 
associated with the synaptic function and a member of 
a highly conserved gene family, together with amyloid 
precursor protein (APP) and amyloid precursor-like pro-
tein 2 (APP2). Several studies have shown co-localization 
of APLP1 with APP in control subjects and Alzheimer’s 
disease brain plaques [31, 32]. In addition, APLP1 is one 
of the substrates of BACE1, an enzyme involved in Alz-
heimer’s disease pathology [33]. Finally, a recent study 
also suggests that APLP1 has significance as a potential 
Fig. 5 Relative abundance of CSF proteome and 78 protein candidates. Shaded dots show 78 protein candidates over the complete proteome. 
Selected 78 brain-specific proteins were positioned in the range of medium- and upper-abundance proteins of the CSF proteome
Fig. 6 GO analysis of 78 protein candidates. The most represented GO molecular functions were binding (35 % of proteins) and receptor activity 
(33 % of proteins)
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biomarker of Parkinson’ disease progression [34]. SCG3, 
part of the granin family involved in the secretory granule 
biogenesis and neurotransmitter storage and transport, 
can be accumulated in the senile plaques of Alzhei-
mer’s disease patients [35]. It has also been reported in 
the context of Parkinson’s disease, in an in  vitro model, 
where SH-SY5Y cell exposure to the neurotoxin paraquat 
resulted in decreased SCG3 expression levels [36]. SCG3 
and SCG2 were previously evaluated as potential bio-
markers of multiple sclerosis and decreased levels were 
observed for SCG3 and SCG2 in serum and CSF samples 
of multiple sclerosis patients [37, 38].
Kallikrein 6 (KLK6) was the most abundant pro-
tein of the group-enriched proteins. KLK6 is one of the 
15-member family of the secreted serine proteases with 
trypsin-like activity. Among all tissues in the body, KLK6 
has the highest expression in the central nervous system 
and high amounts of KLK6 are present in the CSF [39–
41]. It has been suggested that KLK6 may process APP 
and this way contributes to Alzheimer’s disease pathol-
ogy [42, 43]. Several other studies found decreased lev-
els of KLK6 in Alzheimer’s disease brain regions (e.g. 
parietal and frontal cortex) [44, 45]. These findings were 
previously confirmed by our group at the protein level, 
indicating lower KLK6 levels in Alzheimer’s disease brain 
tissue extracts [41, 46]. Studies of KLK6 levels in the CSF 
are still limited and conflicting, showing both low and 
high levels of KLK6 in the Alzheimer’s disease CSF sam-
ples [41, 47]. Recent findings revealed that α-synuclein, 
a protein involved in the pathology of Parkinson’s dis-
ease, is also a potential KLK6 substrate [48–50]. Even 
more intriguing is the finding that overexpression of 
KLK6 in α-synuclein transgenic mouse model leads to 
clearance of α-synuclein, suggesting a potential thera-
peutic application [51]. In contrast, elevated levels of 
KLK6 have been observed in multiple sclerosis patients 
and its role in the disease pathology has been related to 
an immuno-inflammatory pathway, particularly by acti-
vating PAR receptors, key triggers of inflammatory pro-
cesses [52–54]. Here, we evaluated KLK6 protein level 
in the brain tissue extracts and pool of CSF samples as 
a complement of mRNA expression data from HPA 
(KLK6 immunohistochemistry from the HPA not avail-
able). These findings confirmed its abundance in the CSF, 
as well as in the brain tissue extracts, where significantly 
differential levels were observed between brain regions 
(Additional file 7: figure 3).
Another group-enriched protein connected with neu-
rodegenerative diseases and observed with high abun-
dance is a glycosylated phosphoprotein SPP1. A recent 
study revealed its potential as a diagnostic biomarker of 
Parkinson’s disease [34]. SPP1 protein expression was 
found in neurons, Lewy bodies and microglia of substan-
tia nigra region in Parkinson’s disease, pyramidal neurons 
of hippocampus in Alzheimer’s disease (with increased 
levels relative to age-matched controls) and astrocytes 
within plaques and white matter of multiple sclerosis 
patients (with increased levels relative to controls) [55–
57]. SPP1 levels in CSF were also elevated in Alzheimer’s 
disease and mild cognitive impairment [58], and multiple 
sclerosis patients [55, 59].
In conclusion, the present study contributes to the 
existing knowledge of the human CSF proteome and, in 
addition, provides a panel of highly specific brain-derived 
proteins that can be robustly measured in CSF by mass 
spectrometry assays. In future, we intend to develop 
quantitative SRM assays for selected 78 proteins and use 
them as a signature biomarker panel for evaluation of 
various neurodegenerative diseases.
Additional files
Additional file 1: Figure 1.. Proteins common between two samples. 
Venn diagrams show common proteins between any two individual CSF 
samples. The average percentage of common proteins was 66.9 %.
Additional file 2: Figure 2. Peptides common between two samples. 
Venn diagrams show common proteins between any two individual CSF 
samples. The average percentage of common peptides was 74 %.
Additional file 3: Table 1. Brain-enriched proteins of secreted/mem-
brane origin.
Additional file 4: Table 2. Group-enriched proteins of secreted/mem-
brane origin.
Additional file 5: Table 3. 78 tissue-enriched and group-specific 
candidates.
Additional file 6. KLK6 selected reaction monitoring (SRM) assay.
Additional file 7: Figure 3. KLK6 concentration in brain tissue extracts 
and CSF pool. Brain tissue extracts and CSF pool were subjected to mass 
spectrometry sample preparation and analyzed using TSQ Vantage 
(brain tissues) and TSQ Quantiva (CSF) mass spectrometers. One-way 
ANOVA and Bonferroni’s Multiple Comparison Test was performed with 
GradPad Prism between brain regions, n = 3, *p < 0.05. Data are shown 
as mean ± standard error of the mean (SEM). TP- total protein, SNc- sub-
stantia nigra.
Table 4 Representative cell type-specific brain-expressed 
proteins according to  the Human Protein Atlas immuno-
histochemistry data
Ctx cerebral cortex, Hp hippocampus, LV lateral ventricles, Cb cerebellum
Cell type Gene name Staining level Brain region




Neuropil NCAN Medium Ctx
TNR Medium Ctx
CADM3 Medium Ctx
Purkinje cell TMEM132D Low Cb
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